PDK4 expression and tumor aggressiveness in prostate cancer

Eun Hye Lee1, Yun-Sok Ha2, Bo Hyun Yoon1

  • 1Joint Institute of Regenerative Medicine, Kyungpook National University, Daegu, Korea.

Abstract

Insights

Pyruvate dehydrogenase kinase 4 (PDK4) is elevated in prostate cancer, promoting tumor invasion and metastasis. Targeting PDK4 may offer a new therapeutic strategy for advanced prostate cancer, particularly castration-resistant forms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Prostate cancer is a leading cause of cancer mortality worldwide.
  • Metastasis is a critical challenge in prostate cancer management.
  • Pyruvate dehydrogenase kinase 4 (PDK4) regulates aerobic glycolysis and is implicated in various cancers, but its role in prostate cancer is unclear.

Purpose of the Study:

  • To analyze PDK4 expression in prostate cancer cells and human samples.
  • To investigate the clinical significance of PDK4 in prostate cancer.
  • To explore PDK4's role in prostate cancer cell invasion and metastasis.

Main Methods:

  • PDK4 expression was assessed in prostate cancer cell lines and human tissues.
  • Cell migration and invasion were evaluated using Matrigel-coated invasion assays.
  • Epithelial-mesenchymal transition markers and signaling pathways were analyzed after PDK4 knockdown.

Main Results:

  • PDK4 expression was significantly higher in prostate cancer cell lines (DU145, LnCap) and tissues compared to normal controls.
  • PDK4 knockdown suppressed prostate cancer cell invasion and altered epithelial-mesenchymal transition markers.
  • Increased PDK4 expression was observed in castration-resistant prostate cancer, correlating positively with PSA levels.

Conclusions:

  • PDK4 expression is linked to increased tumor invasion and castration status in prostate cancer.
  • PDK4 plays a role in prostate cancer metastasis and invasion pathways.
  • Further research is warranted to validate PDK4 as a potential therapeutic target for prostate cancer.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K